|Related Categories||Apoptosis Inhibitors, Apoptosis and Cell Cycle, Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience,|
|solubility||H2O: <2 mg/mL|
|DMSO: ≥5 mg/mL|
GNF-2 belongs to a new class of Bcr-abl inhibitors. GNF-2 appears to bind to the myristoyl binding pocket, an allosteric site distant from the active site, stabilizing the inactive form of the kinase. It inhibits Bcr-abl phosphorylation with an IC50 of 267 nM, but does not inhibit a panel of 63 other kinases, including native c-Abl, and shows complete lack of toxicity towards cells not expressing Bcr-Abl. GNF-2 shows great potential for a new class of inhibitor to study Bcr-abl activity and to treat resistant Chronic myelogenous leukemia (CML), which is caused the Bcr-Abl oncoprotein.
|Precautionary statements||P261-P305 + P351 + P338|
|Personal Protective Equipment||dust mask type N95 (US), Eyeshields, Gloves|
|Hazard Codes (Europe)||Xi|
|Risk Statements (Europe)||36/37/38|
|Safety Statements (Europe)||26|
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?